SCYNEXIS (SCYX) Competitors

SCYNEXIS (NASDAQ:SCYX) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Do analysts recommend SCYX or PBYI?

Puma Biotechnology has a consensus target price of $7.00, indicating a potential upside of 108.96%. Given Puma Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Puma Biotechnology is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Puma Biotechnology	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor SCYX or PBYI?

In the previous week, SCYNEXIS had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 3 mentions for SCYNEXIS and 2 mentions for Puma Biotechnology. SCYNEXIS's average media sentiment score of 1.00 beat Puma Biotechnology's score of 0.54 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Puma Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in SCYX or PBYI?

Puma Biotechnology received 53 more outperform votes than SCYNEXIS when rated by MarketBeat users. However, 69.56% of users gave SCYNEXIS an outperform vote while only 67.39% of users gave Puma Biotechnology an outperform vote.

Company	Underperform	Outperform
SCYNEXIS	Outperform Votes 505 69.56%	Underperform Votes 221 30.44%
Puma Biotechnology	Outperform Votes 558 67.39%	Underperform Votes 270 32.61%

Do institutionals & insiders have more ownership in SCYX or PBYI?

54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 4.9% of SCYNEXIS shares are held by company insiders. Comparatively, 23.7% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has more volatility and risk, SCYX or PBYI?

SCYNEXIS has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.

Is SCYX or PBYI more profitable?

Puma Biotechnology has a net margin of 9.56% compared to SCYNEXIS's net margin of -425.41%. Puma Biotechnology's return on equity of 41.60% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-425.41%	-66.21%	-38.84%
Puma Biotechnology	9.56%	41.60%	10.71%

Which has stronger valuation & earnings, SCYX or PBYI?

SCYNEXIS has higher earnings, but lower revenue than Puma Biotechnology. SCYNEXIS is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$3.75M	8.02	$67.04M	-$0.56	-1.38
Puma Biotechnology	$232.71M	0.71	$21.59M	$0.77	4.35

Summary

Puma Biotechnology beats SCYNEXIS on 12 of the 18 factors compared between the two stocks.